Antibacterial discovery and development-the failure or success?
Article Abstract:
The development of new antibacterial drugs is constantly going on pharma companies, as they spend a lot on research of newer drugs. It is predicted that a combination of approaches and compounds, many of which failed to yield immediate results in the past, would finally prove invaluable to the drug industry in the battle against infectious disease.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Alfimeprase to succeed Genentech's alteplase?
Article Abstract:
Alfimeprase is being tested in two phase 3 clinical programs for acute peripheral arterial occlusion and catheter occlusion and would succeed altephase of Genentech. Alfimeprase, which would mark a new era in enzyme therapy if successsfully launched, is expected to dominate the blood clot market, which lacks worthy competition.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: First-in-class biologic to enter rheumatoid arthritis fray. Hepatitis C: staying the course
- Abstracts: Army, Raytheon work to make antenna farms history. Raytheon reports mostly improved financial results. Army tests new biodefense system
- Abstracts: Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Avimers hold their own
- Abstracts: Tracking service failures and employee recovery efforts. Franchise relocation and sport introduction: a sports marketing case study of the Carolina Hurricanes' fan adoption plan
- Abstracts: Perceived managerial sincerity, feedback-seeking orientation and motivation among front-line employees of a service organization